For early diagnosis of AD and other neurodegenerative diseases, as well as the development of target-specific therapies for these disorders, it is necessary to understand at the molecular and cellular levels how tau initiates the formation of detrimental tauopathies. The gene discussed is MAPT; the disease is Alzheimer disease.